Slowing progression of, rather than stopping, Alzheimer’s disease has measurable benefits for patients and families and may be a more realistic goal for clinical drug trials, a new report by the American Alzheimer’s Association has suggested.
The report‘s authors call for a “reframing” of how researchers define “clinically meaningful” in randomized controlled trials, adding that they consider it is time to adjust expectations of outcomes from relatively short clinical trials.
The report was published by an expert work group convened by the Alzheimer’s Association. It was prompted, in part, by the US Food and Drug Administration’s controversial decision to grant aducanumab (Aduhelm) accelerated approval, which came over the objection of an advisory panel that found the drug was ineffective.
Slowing, Not Stopping, Alzheimer’s a Better Goal for Drug Trials? (medscape.com)